Tayeb Tayeb C(1), Parc Y(2), Andre T(3), Lopez-Trabada Ataz D(1).
(1)Hopital Saint-Antoine, service d'oncologie medicale, Paris, Fr. (2)Hopital Saint-Antoine, service de chirurgie viscerale, Paris, Fr; Sorbonne Universite, Paris, Fr. (3)Hopital Saint-Antoine, service d'oncologie medicale, Paris, Fr; Sorbonne Universite, Paris, Fr.
Publication
Bull Cancer
Summary
About 15 % of patients with familial adenomatous polyposis "PAF" develop one or more desmoid tumors in their lifetime. These tumors raise a therapeutic problem because of their heterogeneity and the absence of predictive biomarkers along illness evolution. The identification of prognostic biological and clinical factors would make easier the selection of patients requiring first-line treatment, as spontaneous remissions have also been observed in patients with FAP whom which an active surveillance could also be a valid therapeutic option. The particularity of desmoid tumors associated to PAF lies in their predominantly intra-abdominal location and the risk of complication. In the last ten years, surgery has largely given way to conservative treatments such as chemotherapy and more recently to tyrosine kinase inhibitors that have shown their efficacy with a significant improvement in progression-free survival of patients.
Stay Up to Date as We Uncover More About Desmoid Tumors
